Síndromes Coronarios Agudos: evaluación y manejo

Autores/as

  • Jonathan Poveda Fernández Caja Costarricense del Seguro Social, Hospital México
  • Manuel Eduardo Sáenz Madrigal Caja Costarricense del Seguro Social, Hospital Dr. Rafael A. Calderón Guardia

DOI:

https://doi.org/10.51481/amc.v42i3.569

Palabras clave:

Síndrome coronario, Angina inestable, Cardiopatía isquémica

Resumen

El diagnóstico y tratamiento de los pacientes con complicaciones agudas de la enfermedad coronaria, continua siendo un reto a pesar de la ardua investigación realizada en los últimos años con respecto a este tópico. Asimismo, la cardiopatía isquémica, se comporta cada día más como un desafío para la salud pública tanto de países desarrollados como de países en vías de desarrollo. Un millón de pacientes por año son evaluados por presentar síntomas agudos de isquemia miocárdica en los EE.UU. I En 1992, la angina inestable fue el diagnóstico de egreso de 651.000 pacientes en ese país, en 1996, este número aumentó a I .430.000 casos, un número que excede en mucho al de pacientes egresados con diagnóstico de infarto agudo de miocardio (IAM), el cual fue de 350.000 casos. 2 Además el IAM no Q, es culpable del 30% de todos los internamientos por infarto agudo miocárdico. 34

El reconocimiento temprano de los síndromes coronarios agudos (SCA) descritos anteriormente, así como su adecuado abordaje terapeútico, representa un reto para la múltiple gama de profesionales involucrados en su manejo (médicos generales, emergenciólogos, internistas, intensivistas, cardiólogos y cardiólogos intervencionistas). Esta revisión pretende, de forma concisa, presentar los más recientes avances en cuanto al diagnóstico y terapéutica de este complejo síndrome.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Graves EJ. National Hospital discharge survey. Annual survey 1996 Series 13, no. 14. Washington D,C,: National Center for Health Statistics, 1998.

Detailed diagnoses, and procedures. National Hospital Discharge Survey. National Center for Health Statistics. Vital Health Stat. 1998: 1996: 13: 138.

Cairns J, Theroux P. Armstrong R Bogarty P. Wells C, Thompson C. Warnica W. Report from a Canadian expert round table. Can J Card 1996: 12: 1279-1292.

Theroux P, Fuster V. ACS. Unstable angina and Non Q wave Ml. Cardiology new frontiers. Circulation 1998, 97 : 1 195-1206.

Califf RM. Acute ischemic syndromes. Med Clin of NA 1995, 79(5): 999-1203.

Klootwjik P. Hamm C. Acute coronary syndromes: diagnosis. Lancet,1999: (suppl ll): 10-5

Theroux P. Fuster V. Acute coronary syndromes. Circulation 1998: 97: 1195-1206.

Yeghiazarians Y. et al. Unstable angina pectoris. N Engl J Med

Libby P. Molecular basis of the acute coronary syndromes. Circulation 1995; 91: 2844-50.

Ambrose JA, Winters SL, Arora RR, Riccio A, Gorlin R, et al. Angiographic evolution Of coronary artery morphology in unstable angina. J Am coli Cardiol 1986; 7: 472-78.

Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction or sudden death. Circulation 1985; 71: 699-708.

Fuster V, Fayad Z, Badimon J. Acute coronary syndromes: Biology. Lancet 1999; 353 (Suppl. 11): 5-9.

Cannon CR Mccabe CM, Stone DM, et al. ECG predicts one year outcome of patients with unstable angina and non Q wave myocardialinfarction: Results of TIMI 111B Registry ECG ancillary studies. J Am Coli Cardiol 1997; 30: 133-140.

Seronnito S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281:707-713.

Roberts R, Parker CW, Sobel BE. Detection of acute myocardial infarction by radioinmunoassay for CKMB. Lancet 1977, 2: 319-322.

Puleo PR, Gradagno PA, Roberts R, et al. Early diagnosis of acute myocardial infarction based on assay subforms of CK-MB. Cirulation 1990; 82: 759-64.

Hamm CW, Raukilde J, Gerhart W, et al. The prognostic value of troponin T in unstable angina. N Engl J Med 1992; 377:146-50

Antman EM, Tanasijevic MI, Thompson B, et al, Cardiac specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342-1349.

Morron PA, Rifar N, Antarnem EM, et al. C reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes. J Am Coll Cardiol 1998: 31: 1460-1465.

Stratmann HG, Younis LT. Wittry MD, Amato M, Miller DD. Exercise Technetium 99m myocardial tomography for risk stratification of man with medially treated unstable angina pectoris. Am J Cardiol 1995: 76: 236-240

Fayed ZA. Taumena N, Badimon J, et al. MRI of human atherosclerotic aorta in vivo. Circulation 1998; 98:1 515 Abstract.

Roth GS, Majerus DW. The mechanism of the effect of aspirin in human platelets: acetylation of a particular fraction proteins. J ClinInvest 1975: 56: 624-632.

ISIS-2 (Second International Study of Infarct Survival) Colaborative group Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.

Lewis HE), Davis JW. Archibald DG. Steinke WE, Smitherman AZ, Doherty AE. et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983: 309: 396-403.

Cairns JA. Grant M, Singer J, Finnie KJ, Froggafl GM, Holder DA, et al. Aspirin, sulfinpirazone or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985: 313: 1369-1375.

Theroux P. Ouitment H. McCans J, Latour JG. Levy G, et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988

The RISC group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990: 336: 827-830.

Patrono C, Collar B. Dalen J. Fuster V, Gent M, Harker L, etal. Platelet active drugs: the relationship among dose, effectiveness and side effects. Chest 1988: 114: 470S-488S.

Antry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-1218.

CAPRIE Steering Comitee. A randomized blinded trial of clopidrogel vs. aspirin in patients at risk of ischemic events. Lancet 1996; 348' 1234-1239.

Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina a controlled multicenter clinical trial. Circulation 1990; 82: 17-26.

Benett CL, Connors JM. Carwail JM, et al. Thrombotic thrombocytopenic purpura associated with clopidrogel. N Engl J Med 2000: 342:1773-7

Mousar I, Oetgens M, Roubin G, et al. Effectiveness of Clopidrogel and aspirin vs. Ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99: 2364-2366.

The PARAGON investigators. And intemational, randomized controlled trial of lamifiban, a platelet glycoprotein 11b/IlIa inhibitor. heparin, or both in unstable angina. Circulation. 1988: 97: 2386-2395.

The Platelet Receptor inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms (PRISM PLUS) Study investigators. Inhibition of the platelet glycoprotein 11b/IIla receptor with Tirofiban in Unstable angina and Non - Q wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.

The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein 11b/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-433.

Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet pre-eminence. Circulation 1998: 97: 21 1-213.

The RESTORE investigators. Effects of platelet glycoprotein 11b/IIla blockade with Tirofiban, on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997: 96: 1445-1447.

Cannon CP. McCabe Cm. Borzak S, et al. Randomized trial of and oral antiplatelet glycoprotein 11b/Illa antagonist, sibrofiban in patients after acute coronary syndromes. Results of TIMI 12 trial. Circulation 1998: 97: 340-349.

Kereiakes DJ. Kleinhman NS, Ferguson J. et al. Pharmacodynamic efficacy. clinical safety and outcomes after prolonged platelet glycoprotein 11b/IIIa receptor blockade with oral xemlofiban: results of a multicenter, placebo, controlled randomized trial. Circulation 1998:98: 1268-1278.

Ferguson JJ, Deedwania DC, Kereiakes DJ, et al. Sustained plateletglycoprotein 11b/IIIa blockade with oral orbofiban: interin pharmacodynamic results of the SOAR study. J Am Coll Cardiol 1998: 31 (Suppl A): 185A Abstract.

Oler A, Whooley MA. Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction in patients with unstable angina: a meta-analysis. JAMA 1996: 276;811-815.

Warkentin TE, Levine MN, Hirsh J. et al. Heparin induced thrombocitopenia in patients treated with LMWH or unfractioned heparin N Engl J Med 1995; 332: 1330-35

Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH. Califf RM, et al. ACC/AHA Guidelines for the management Of patients with AMI: A report of ACC/AHA Task Force on practice guidelines. Comitee on management of acute myocardial infarction. J Am Coll Cardiol 1996; 28:1328-1428. 1999 Update: Circulation 1999: 1016- 1030.

Hirsh J, Levine M. Low molecular weigth heparins. Blood. 1993: 79: 1-17.

Weitz JL. Low molecular weigth heparins. N Engl J Med 1 997: 337:1567-75.

Packer M, Briston MR, Cohn JIN, Colucci WS, Fowler MB. Gilgert EM, et al. The effect of carvedilol on morbidity and mortality in patients with cronic heart failure. N Engl J Med 1996; 334:1349-1355.

Wilcox RG, Hampton JR, Banes DC, Birkhead JS, Browser IA. Bumstox CJ, et al. Trial of early nifedipine in acute myocardial infarction: The Trent study. BMJ 1986: 293: 1204-1248.

Gibson RS, Boden WE, Theroux P, Strauss HD. Pratt CM. Gheorgidde M, et al. Diltiazem and reinfarction in patients with non Q - wave myocardial infarction . Results Of a double blind, randomized trial . N Engl J Med 1986; 315: 423-429.

Pfeffer MA, Braunwald E, Moye LA. Bar-ta C. Byon ES. Cuddy TE. et. al. Effect of ramipril on mortality and morbidity patients with left ventricular disfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677.

The Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Effect of ramipril on mortality and morbidity Of survivors Of acute myocardial infarction with clinical evidence heart failure. Lancet 1993; 342: 521-528.

HOPE investigators. Effects of and angiotensin convening enzyme inhibition, ramipril, On cardiovascular events in high risk patients. N Engl J Med 2000: 342:145-53.

HOPE study investigators. Effects Of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and micro-HOPE substudy. Lancet 355: 253-259.

Boden NE. O'rourke RA. Crawford MH. Blenstein AJ, Deedwania DL. Zoble RG. et al. Outcomes in patients with acute myocardial infarction ramdomly assigned to an invasive as compared with consen'ative strategy. N Engl J Med 1998: 378: 1785-1792.

Hillis I-D. Rutherford JD. Coronary angioplasty compared with bypass grafting. N Engl J Med 1994; 331: 1086-1087.

Versaci F. Gaspardore A, Tomai F. Crea F. Chigriello L. Gioffre PA. A comparison of coronary artery stenting with angioplasty for isolated stenosis of proximal left anterior descending coronary artery N Engl J Med 1997: 336: 817-822.

Savage MP, Dougals AS. Fischman LDL. Pepine CJs Kiny SB, Werner JA, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med 1997: 337: 740-747.

Cannon AD, Roubin GS, Macunder PS, Agrawal SK. Intracoronary stent as and adjunct to angioplasty in acute myocardial infarction. J Inv Cardiol 1991; 3: 255-258.

Serruys PW, de Joegne P, Kiemeneij F, Macaya L, Rutsem W. Heydrickx G, et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994: 331: 486-495.

Fischrnan DL, Leon MB, Bairn ps, Schatz DA. Savage MD. Deon 1. et. al. A randomized comparison Of coronary Stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331; 496-501.

The EPIC investigators, Use of a monoclonal antibody directed against the platelet glycoprotein 11b/IlIa receptor in high risk coronary angioplasty, N Engl J Med 1994: 330: 956-961.

Descargas

Publicado

2000-07-01

Cómo citar

Poveda Fernández, J., & Sáenz Madrigal, M. E. (2000). Síndromes Coronarios Agudos: evaluación y manejo. Acta Médica Costarricense, 42(3), 101–108. https://doi.org/10.51481/amc.v42i3.569

Artículos similares

También puede {advancedSearchLink} para este artículo.